Alps Advisors Inc. cut its stake in shares of Autolus Therapeutics plc (NASDAQ:AUTL – Get Rating) by 42.3% during the second quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 53,931 shares of the company’s stock after selling 39,502 shares during the quarter. Alps Advisors Inc.’s holdings in Autolus Therapeutics were worth $153,000 at the end of the most recent quarter.
A number of other institutional investors and hedge funds have also made changes to their positions in AUTL. Frazier Life Sciences Management L.P. acquired a new position in shares of Autolus Therapeutics during the 1st quarter worth $15,624,000. Deep Track Capital LP acquired a new position in shares of Autolus Therapeutics during the 1st quarter worth $1,595,000. MAI Capital Management acquired a new position in shares of Autolus Therapeutics during the 2nd quarter worth $1,034,000. Nantahala Capital Management LLC grew its stake in shares of Autolus Therapeutics by 6.6% during the 1st quarter. Nantahala Capital Management LLC now owns 4,346,327 shares of the company’s stock worth $18,124,000 after purchasing an additional 268,818 shares during the period. Finally, Goldman Sachs Group Inc. grew its stake in shares of Autolus Therapeutics by 144.8% during the 1st quarter. Goldman Sachs Group Inc. now owns 375,514 shares of the company’s stock worth $1,566,000 after purchasing an additional 222,093 shares during the period. 55.06% of the stock is owned by institutional investors and hedge funds.
Analysts Set New Price Targets
Separately, Needham & Company LLC lowered their price target on shares of Autolus Therapeutics from $13.00 to $12.00 and set a “buy” rating on the stock in a research note on Friday, August 5th.
Autolus Therapeutics Price Performance
Autolus Therapeutics Company Profile
Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which is in a Phase 1 clinical trial in pediatric patients with relapsed or refractory ALL; AUTO4, a programmed T cell investigational therapy for the treatment of peripheral T-cell lymphoma targeting TRBC1; AUTO6NG, a programmed T cell investigational therapy, which is in preclinical trail targeting GD2 in development for the treatment of neuroblastoma; and AUTO8, a product candidate that is in a Phase I clinical trial for multiple myeloma.
- Get a free copy of the StockNews.com research report on Autolus Therapeutics (AUTL)
- Salesforce Cuts Labor, Shows Strong Earnings Despite Challenges
- Microsoft Shares: Is it Time to Back Up the Truck?
- Is the 60/40 Portfolio Mix Still in Vogue?
- Three CBD Stocks to Dominate a Budding Industry
- Institutional Support for Analog Devices Remains High
Receive News & Ratings for Autolus Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Autolus Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.